NEW YORK, United States, April 17 – Pharmaceutical giant Merck announced Sunday the purchase of California-based biotech company Prometheus Biosciences for nearly $11 billion. The two companies “have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash…Read More
Drugmaker Merck acquires Prometheus for nearly 11 bn
